$ELDN
Eledon Pharmaceuticals, Inc.

2021 Q2 Form 10-Q Financial Statement

#000156459021044038 Filed on August 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.729M $1.270M $1.730M
YoY Change 193.62% -29.05% -8.47%
% of Gross Profit
Research & Development $4.242M $830.0K $1.648M
YoY Change 411.08% -63.87% -44.88%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $7.971M $2.100M $3.378M
YoY Change 279.57% -48.64% -30.78%
Operating Profit -$7.971M -$3.378M
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$1.000K $10.00K $30.00K
YoY Change -110.0% -350.0% -600.0%
Pretax Income -$7.972M -$2.590M -$8.177M
YoY Change 207.8% -36.67% 67.56%
Income Tax -$588.0K
% Of Pretax Income
Net Earnings -$7.384M -$2.586M -$8.177M
YoY Change 185.54% -36.82% 67.53%
Net Earnings / Revenue
Basic Earnings Per Share -$0.50
Diluted Earnings Per Share -$0.50 -$2.755M -$8.521M
COMMON SHARES
Basic Shares Outstanding 14.82M 16.07M
Diluted Shares Outstanding 14.82M

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $101.1M $8.800M $11.80M
YoY Change 1049.24% -35.77% 29.67%
Cash & Equivalents $101.1M $8.764M $11.79M
Short-Term Investments
Other Short-Term Assets $11.00K $83.00K $64.00K
YoY Change -86.75% 6.41% 137.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $102.6M $9.800M $12.90M
YoY Change 946.76% -35.45% 24.99%
LONG-TERM ASSETS
Property, Plant & Equipment $267.0K $200.0K $300.0K
YoY Change 33.5% 1900.0% 2400.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $422.0K $500.0K $572.0K
YoY Change -15.6% -33.77% -28.5%
Total Long-Term Assets $81.72M $700.0K $820.0K
YoY Change 11574.71% -76.94% -74.21%
TOTAL ASSETS
Total Short-Term Assets $102.6M $9.800M $12.90M
Total Long-Term Assets $81.72M $700.0K $820.0K
Total Assets $184.3M $10.50M $13.72M
YoY Change 1655.29% -42.36% 1.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $857.0K $200.0K $741.0K
YoY Change 328.5% -73.44% 48.2%
Accrued Expenses $1.820M $900.0K $1.100M
YoY Change 102.22% -25.0% -60.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.677M $1.100M $1.878M
YoY Change 143.36% -43.53% -42.05%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $90.00K $0.00 $100.0K
YoY Change -100.0% -66.67%
Total Long-Term Liabilities $90.00K $0.00 $100.0K
YoY Change -100.0% -66.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.677M $1.100M $1.878M
Total Long-Term Liabilities $90.00K $0.00 $100.0K
Total Liabilities $5.784M $1.100M $2.000M
YoY Change 425.82% -49.63% -43.21%
SHAREHOLDERS EQUITY
Retained Earnings -$96.30M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $178.5M $9.356M $11.75M
YoY Change
Total Liabilities & Shareholders Equity $184.3M $10.50M $13.70M
YoY Change 1655.29% -42.36% 1.85%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income -$7.384M -$2.586M -$8.177M
YoY Change 185.54% -36.82% 67.53%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change
Cash From Operating Activities -$7.442M -$3.020M -$2.197M
YoY Change 146.42% -38.74% -45.39%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 5.191M
YoY Change -100.0% 4751.4%
NET CHANGE
Cash From Operating Activities -7.442M -3.020M -2.197M
Cash From Investing Activities
Cash From Financing Activities 0.000 0.000 5.191M
Net Change In Cash -7.442M -3.020M 2.994M
YoY Change 146.42% -165.09% -176.46%
FREE CASH FLOW
Cash From Operating Activities -$7.442M -$3.020M -$2.197M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
eldn Cancellation Of Common Stock In Exchange For Preferred Stock Shares
CancellationOfCommonStockInExchangeForPreferredStockShares
6204
us-gaap Net Income Loss
NetIncomeLoss
-15883000
CY2021Q2 us-gaap Shares Outstanding
SharesOutstanding
6204
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
178521000
CY2021Q1 us-gaap Shares Outstanding
SharesOutstanding
6204
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
183871000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2034000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-7384000
CY2021Q2 us-gaap Shares Outstanding
SharesOutstanding
6204
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
178521000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
9465000
eldn Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5191000
us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
-3285
eldn Cancellation Of Common Stock In Exchange For Preferred Stock Shares
CancellationOfCommonStockInExchangeForPreferredStockShares
3796
eldn Warrants Issued During Period Inducement Expense
WarrantsIssuedDuringPeriodInducementExpense
4829000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
634000
us-gaap Net Income Loss
NetIncomeLoss
-10763000
CY2020Q2 us-gaap Shares Outstanding
SharesOutstanding
511
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
9356000
CY2020Q1 us-gaap Shares Outstanding
SharesOutstanding
3796
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
11745000
CY2020Q2 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
-3285
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
197000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2586000
CY2020Q2 us-gaap Shares Outstanding
SharesOutstanding
511
us-gaap Net Income Loss
NetIncomeLoss
-15883000
us-gaap Net Income Loss
NetIncomeLoss
-10763000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4000
eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
90000
eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
88000
eldn Warrant Inducement Expense
WarrantInducementExpense
4829000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3808000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
634000
eldn Deferred Tax Liability
DeferredTaxLiability
1089000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
53000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-311000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
609000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-233000
eldn Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-94000
eldn Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-88000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12612000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5218000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5191000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
450000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-450000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5191000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13062000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114195000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8791000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
101133000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8764000
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
1000
eldn Increase In Operating Lease Asset And Liability Due To Lease Modification
IncreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification
219000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-7400000
us-gaap Net Income Loss
NetIncomeLoss
-15900000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
101100000
CY2021Q2 eldn Working Capital
WorkingCapital
99900000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.58%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to stock-based transactions, accruals for liabilities, fair value of assets acquired and liabilities assumed in a business combination, impairment of long lived assets, including goodwill, and other matters that affect the condensed consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the <span style="color:#000000;">condensed </span>consolidated financial statements. </p>
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.07
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-11.31
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14815731
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
943419
eldn Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
three months or less
CY2021Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
9200000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
9200000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-7384000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2586000
us-gaap Net Income Loss
NetIncomeLoss
-15883000
us-gaap Net Income Loss
NetIncomeLoss
-10763000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.74
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14823348
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
951352
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5089938
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
457442
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.29%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain reclassifications of prior period amounts have been made to conform to the current period presentation.</p>
CY2021Q2 us-gaap Prepaid Insurance
PrepaidInsurance
627000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1157000
CY2021Q2 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
641000
CY2020Q4 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
89000
CY2021Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
83000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
41000
CY2021Q2 us-gaap Insurance Settlements Receivable Current
InsuranceSettlementsReceivableCurrent
87000
CY2020Q4 us-gaap Insurance Settlements Receivable Current
InsuranceSettlementsReceivableCurrent
110000
CY2021Q2 us-gaap Other Assets Current
OtherAssetsCurrent
11000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
38000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1449000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1435000
CY2021Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
656000
CY2020Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
31000
CY2021Q2 eldn Accrued Severance Current
AccruedSeveranceCurrent
261000
CY2020Q4 eldn Accrued Severance Current
AccruedSeveranceCurrent
12000
CY2021Q2 eldn Accrued Clinical Current
AccruedClinicalCurrent
413000
CY2020Q4 eldn Accrued Clinical Current
AccruedClinicalCurrent
258000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
118000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
9000
CY2021Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
176000
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
67000
CY2020Q4 eldn Accrued Financing Costs
AccruedFinancingCosts
450000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
17000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
146000
CY2021Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1641000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
973000
CY2021Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
63000
CY2020Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
47000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
126000
CY2021Q2 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
93000
us-gaap Operating Lease Cost
OperatingLeaseCost
98000
us-gaap Operating Lease Payments
OperatingLeasePayments
97000
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0318
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
94000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
181000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
275000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
269000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
179000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
90000
CY2021Q2 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2021Q2 eldn Contingent Liability
ContingentLiability
0
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2034000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
197000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3808000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
634000
CY2020Q2 eldn Business Acquisition Pro Forma Net Income Loss And Other Comprehensive Income Loss
BusinessAcquisitionProFormaNetIncomeLossAndOtherComprehensiveIncomeLoss
-3430000
eldn Business Acquisition Pro Forma Net Income Loss And Other Comprehensive Income Loss
BusinessAcquisitionProFormaNetIncomeLossAndOtherComprehensiveIncomeLoss
-13727000
CY2020Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
9000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
39000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
0

Files In Submission

Name View Source Status
0001564590-21-044038-index-headers.html Edgar Link pending
0001564590-21-044038-index.html Edgar Link pending
0001564590-21-044038.txt Edgar Link pending
0001564590-21-044038-xbrl.zip Edgar Link pending
eldn-10q_20210630.htm Edgar Link pending
eldn-10q_20210630_htm.xml Edgar Link completed
eldn-20210630.xsd Edgar Link pending
eldn-20210630_cal.xml Edgar Link unprocessable
eldn-20210630_def.xml Edgar Link unprocessable
eldn-20210630_lab.xml Edgar Link unprocessable
eldn-20210630_pre.xml Edgar Link unprocessable
eldn-ex311_9.htm Edgar Link pending
eldn-ex312_7.htm Edgar Link pending
eldn-ex321_6.htm Edgar Link pending
eldn-ex322_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending